Stage-Specific Alteration and Prognostic Relationship of Serum Fumarate Hydratase Autoantibodies in Gastric Cancer

Area of Science:

• Oncology
• Biochemistry
• Immunology

Background:

• The link between cellular energy production and cancer development is an area of growing interest.
• Fumarate hydratase (FH), an enzyme crucial for energy metabolism via the tricarboxylic acid cycle, has been implicated in various cancers.
• Autoantibodies against FH (s-FH-Ab) are being explored as potential biomarkers in cancer diagnostics.

Purpose of the Study:

• To investigate the clinical and pathological significance of serum FH autoantibody (s-FH-Ab) levels in gastric cancer.
• To evaluate s-FH-Ab as a potential biomarker for early diagnosis and prognosis prediction in gastric cancer patients.

Main Methods:

• Analysis of preoperative serum s-FH-Ab titers in 116 gastric cancer patients and 96 healthy controls using an amplified luminescent proximity homogeneous assay.
• Utilizing receiver operating characteristic (ROC) analysis to establish a cutoff s-FH-Ab titer.
• Comparing clinicopathological factors and patient prognosis between high and low s-FH-Ab groups.

Main Results:

• Gastric cancer patients exhibited significantly higher s-FH-Ab levels compared to healthy controls (p=0.01).
• Elevated s-FH-Ab levels were observed even in Stage I gastric cancer patients (p=0.02).
• Low s-FH-Ab levels correlated significantly with distant metastasis (p=0.01), peritoneal dissemination (p<0.05), and poorer overall survival (p<0.01).
• Multivariate analysis identified low s-FH-Ab levels as an independent risk factor for poor prognosis (p<0.01).

Conclusions:

• Serum FH autoantibody levels show potential as a valuable biomarker for the early detection of gastric cancer.
• s-FH-Ab levels can serve as an independent predictor of prognosis in gastric cancer patients.
• Further research into s-FH-Ab could lead to improved diagnostic and therapeutic strategies for gastric cancer.